

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



*(Incorporated in the Cayman Islands as an exempted company with limited liability)*

**(Stock code: 1873)**

## **PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Viva Biotech Holdings (the “**Company**”) together with its subsidiaries, the “**Group**”) announces that Mr. WANG Stephen Hui (王暉, “**Mr. Wang**”) has been nominated as a non-executive Director. Such appointment is subject to the approval of the shareholders (the “**Shareholder(s)**”) of the Company at the upcoming extraordinary general meeting of the Company.

The biographical details of Mr. Wang is set out below:

Mr. Wang, aged 50, has served as the chief executive officer of HighLight Capital since 2014, leading the fund in investments in the healthcare and consumer technology industries. Prior to joining HighLight Capital, he served as a partner and a member of investment committee of CDH Investments from 2009 to 2014. He is currently a non-executive director of Zylox-Tonbridge Medical Technology Co., Ltd. (歸創通橋醫療科技股份有限公司), a company listed on the main board of The Stock Exchange of Hong Kong Limited with the stock code 2190.

Mr. Wang received a bachelor’s degree in biology from the University of Science and Technology of China in the PRC in July 1996 and a master’s degree in chemistry from New York University in the United States in May 1998, and an M.B.A. degree from London Business School in the United Kingdom in August 2007.

As of the date of this announcement, Mr. Wang is interested in 85,000,000 shares of the Company through HLC VGC Partners HK II Limited (“**HLC SPV**”), HLC SPV is in turn owned and controlled by VGC Fund IV L.P (an exempted limited partnership formed under the laws of the Cayman Islands) whose general partner is HLC VGC GP IV Limited, which is ultimately owned by Mr. Wang. In Addition, HLC SPV is also interested in US\$2.891 million of the registered capital (representing approximately 4.38% of the total registered capital) of Viva Biotech (Shanghai) Ltd. (維亞生物科技(上海)有限公司), a non-wholly owned subsidiary of the Company.

The term of Mr. Wang's services as a non-executive Director is for three years commencing the date upon which the Shareholders of his appointment at the upcoming extraordinary general meeting and is subject to retirement and re-election at the annual general meetings of the Company pursuant to the articles of association of the Company. Mr. Wang has entered into an appointment letter with the Company which shall take effect upon the Shareholders' approval of his appointment at the upcoming extraordinary general meeting, Mr. Wang will not be entitled to an annual director's fee in relation to his proposed appointment.

As at the date of this announcement and save as disclosed above, Mr. Wang confirms that he did not have any relationship with any director, senior management, chief executive or substantial shareholder or controlling shareholder of the Company and hold no other position within the Group. Within the meaning of Part XV of the Securities and Futures Ordinance, Mr. Wang also confirms that he does not have any interest in the shares or underlying shares of the Company and he has not held any directorship in other listed public companies in Hong Kong or overseas in the last three years and he does not have any major appointments and professional qualifications. There is no other matter that needs to be brought to the attention of the Shareholders and there is no other information which is required to be disclosed pursuant to any of the requirements of rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

A circular, together with a notice convening an extraordinary general meeting, containing, inter alia, details of the proposed appointment of Mr. Wang as a non-executive Director will be dispatched to the Shareholders in accordance with the Listing Rules.

By order of the Board  
**Viva Biotech Holdings**  
**Mao Chen Cheney**  
*Chairman and Chief Executive Officer*

Hong Kong, December 22, 2023

*As at the date of this announcement, the Board comprises three Executive Directors, namely, Mr. Mao Chen Cheney (Chairman), Mr. Wu Ying and Mr. Ren Delin; a Non-executive Director, namely, Mr. Wu Yuting; and three Independent Non-executive Directors, namely, Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang.*

\* *For identification purposes*